

**The 27th Annual Meeting of The Japanese Breast Cancer Society  
Category List**

| Categories  | Theme   |   |   |
|---|---|---|---|
| <b>A- Basic Science</b>   | A-01 Genomics   | A-02 Epigenetics  | A-03 Proteomics                                     |
|   | A-04 Oncogenetics   | A-05 Hormone receptor                                     | A-06 Cell cycle/ DNA damage and repair              |
|   | A-07 Transcriptional regulation and signal transduction                   | A-08 Drug resistance                                      | A-09 Cancer stem cells                              |
|   | A-10 Epithelial-Mesenchymal Transition                                    | A-11 Invasion, metastasis                                 | A-12 Microenvironment/Angiogenesis                  |
|   | A-13 Tumor immunology   | A-14 Micro RNA  | A-15 Drug delivery system                           |
|   | A-16 Others (Basic Science)   |   |   |
| <b>B- Screening and Prevention</b>                                    |   |   |   |
| <b>C- Imaging</b>   | C-01 Mammography  | C-02 Ultrasonography                                      | C-03 MRI  |
|   | C-04 CT•PET-CT  | C-05 New imaging  | C-06 Others (Imaging)                               |
| <b>D- New diagnostics</b>   |   |   |   |
| <b>E- Pathology</b>   |   |   |   |
| <b>F- Intervention</b>  |   |   |   |
| <b>G- Prognostic marker/ predictive marker/ liquid biopsy/ others</b> | G-01 Prognostic marker  | G-02 Predictive marker                                    | G-03 Companion diagnosis                            |
|   | G-04 Liquid biopsy  | G-05 Circulating tumor cell                               | G-06 Circulating tumor DNA                          |
|   | G-07 Others (Prognostic marker/ predictive marker/ liquid biopsy/ others) |   |   |
| <b>H- Public health</b>   | H-01 Health care epidemiology   | H-02 Genome epidemiology                                  | H-03 Pharmacoepidemiology                           |
|   | H-04 Health care economics  | H-05 Medical ethics                                       | H-06 Molecular epidemiology                         |
|   | H-07 Biostatistics  | H-08 Preventive service, Health care informatics          | H-09 Others (Public health)                         |
| <b>I- Medical communication</b>                                       |   |   |   |
| <b>J- Women's health</b>  | J-01 Cancer risk management and prevention                                | J-02 Diagnosis and treatment                              | J-03 Fertility, Others                              |
| <b>K- Hereditary breast cancer</b>                                    | K-01 Genetic testing  | K-02 Genetic counseling                                   | K-03 Biology  |
|   | K-04 Clinicopathological characteristics                                  | K-05 Prevention, Risk reduction                           | K-06 Others (Hereditary breast cancer)              |
| <b>L- Surgery</b>   | L-01 Sentinel lymph node biopsy   | L-02 Neoadjuvant systemic therapy and axillary management | L-03 Breast conserving treatment                    |
|   | L-04 Ipsilateral breast recurrence  | L-05 Minimally invasive surgery                           | L-06 Non-surgical ablation                          |
|   | L-07 Cosmetics  | L-08 Surgery for loco-regional recurrence                 | L-09 Surgery for distant metastasis                 |
|   | L-10 Surveillance   | L-11 Perioperative nursing                                | L-12 Medical devices                                |
|   | L-13 Others (Surgery)   |   |   |
| <b>N- Oncoplastic surgery/Breast reconstruction</b>                   |   |   |   |
| <b>M- Radiation Therapy</b>   | M-01 Breast conserving therapy  | M-02 PMRT   | M-03 Neoadjuvant systemic therapy                   |
|   | M-04 Toxicities   | M-05 New methodologies and devices                        | M-06 Radiation to metastasis and distant recurrence |
|   | M-07 Nursing related to radiation therapy                                 | M-08 Others (Radiation Therapy)                           |   |
| <b>O- Systemic therapy</b>  | O-01 Neoadjuvant hormone therapy  | O-02 Neoadjuvant chemotherapy                             | O-03 Neoadjuvant molecular targeting therapy        |
|   | O-04 Adjuvanted hormone therapy   | O-05 Adjuvanted chemotherapy                              | O-06 Adjuvanted molecular targeting therapy         |
|   | O-07 Metastatic breast cancer   | O-08 Luminal  | O-09 HER2 positive                                  |
|   | O-10 Triple negative  | O-11 Immunotherapy  | O-12 New therapeutics                               |
|   | O-13 Patient support and compliance                                       | O-14 Safety management                                    | O-15 Others (Systemic therapy)                      |
| <b>P- Team Oncology</b>   | P-01 Patients' satisfaction   | P-02 Prevention and control of toxicity                   | P-03 Pain control                                   |
|   | P-04 Lymphedema   | P-05 Management of adverse event                          | P-06 Role of pharmacist                             |
|   | P-07 Role of Nurse  | P-08 Medical IT   | P-09 Others (Team Oncology)                         |
| <b>Q- Specific situation and disease type</b>                         | Q-01 Breast cancer in young women   | Q-02 Breast cancer in elderly women                       | Q-03 Male breast cancer                             |
|   | Q-04 Bilateral breast cancer  | Q-05 Special pathological type disease                    | Q-06 Inflammatory breast cancer                     |
|   | Q-07 Locally advanced breast cancer                                       | Q-08 Occult breast cancer                                 | Q-09 Comorbidity and QOL                            |
|   | Q-10 Others (Specific situation and disease type)                         |   |   |
| <b>R- Palliative care</b>   |   |   |   |
| <b>S- Survivorship</b>  |   |   |   |
| <b>T- Psychosocial support</b>  | T-01 Psycho-oncology  | T-02 Patient advocacy and social networking               | T-03 Others (Psychosocial support)                  |
| <b>U- Integrative medicine</b>  | U-01 Complementary and alternative medicine                               | U-02 Others (Integrative medicine)                        |   |
| <b>V- Clinical trials</b>   |   |   |   |
| <b>W- Big data analysis</b>   | W-01 Bioinformatics   | W-02 Medical record and registry                          | W-03 Imaging, pathology, others                     |
| <b>X- AI (artificial intelligence)</b>                                | X-01 OMICS  | X-02 Clinical application                                 | X-03 Drug discovery, others                         |
| <b>Y- Case report</b>   | Y-01 Diagnosis  | Y-02 Surgery  | Y-03 Systemic therapy                               |
|   | Y-04 Radiation therapy  | Y-05 Palliative care                                      | Y-06 Clinical course                                |
|   | Y-07 Nursing  | Y-08 Others (Case report)                                 |   |
| <b>Z- Life style, work style, training</b>                            | Z-01 Gender equality and work-life balance                                | Z-02 Cultivation of human resources                       | Z-03 Others (Life style, work style and training)   |